Massive review probes hepatitis c pill safety in drug users

NCT ID NCT07419347

Recruiting now Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks back at medical records of 2,000 people with hepatitis C who took an 8-week course of glecaprevir/pibrentasvir (G/P). The goal is to see how safe and effective the treatment is for those also taking prescription or illegal drugs. Researchers will track side effects and liver enzyme changes to better understand real-world risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C VIRUS (HCV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C VIRUS (HCV)

Contacts and locations

Locations

St. Clair Medical Clinic /ID# 275334
RECRUITING

Toronto, Ontario, M4S 1Y2, Canada
Vancouver Infectious Diseases Centre /ID# 275313
RECRUITING

Vancouver, British Columbia, V6Z 2C7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.